Merck KGaA snaps up BeiGene's 'Made in China' BRAF inhibitor
This article was originally published in Scrip
In the past, Chinese companies used to act mainly as simple partners to develop and commercialize foreign firms' new drugs in China. But as more companies in this country begin to value innovation over manufacturing, it is now no longer rare for multinationals to seek out and acquire rights to a novel "Made in China" drug for global development.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.